Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Carlo Morosi(Fondazione IRCCS Istituto Nazionale dei Tumori), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Thomas Brodowicz(Vienna General Hospital), Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), Angelo Paolo Dei Tos(University of Padua), Hans Gelderblom(Leiden University Medical Center), R. Biagini(Tumori Foundation), Stefan Bielack(Olgahospital), Sebastian Bauer(Science for Life Laboratory), Virginia Ferraresi(Cancer Institute (WIA)), Kateřina Kopečková(University Hospital in Motol), Akira Kawai(NTT (Japan)), Rick L. Haas(Leiden University Medical Center), Ofer Merimsky(Tel Aviv Sourasky Medical Center), Mikael Eriksson(Herlev Hospital), Michael Montemurro(University Hospital of Lausanne), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Peter Hohenberger(University of Mannheim), Dagmar Adámková Krákorová(Masaryk Memorial Cancer Institute), Armelle Dufresne(Centre Léon Bérard), Christina Messiou(Institute of Cancer Research), Robin L. Jones(Institute of Cancer Research), Giovanni Grignani(Candiolo Cancer Institute), Kjetil Boye(Oslo University Hospital), А. А. Феденко(P.A. Hertzen Moscow Oncology Research Institute), Anna Maria Frezza(University of Milan), Xavier García del Muro(Institut Català d'Oncologia), Sylvie Bonvalot(Dana-Farber Cancer Institute), Angela Buonadonna(Centro di Riferimento Oncologico), Eric Legius(Center for Human Genetics), Aisha Miah(Institute of Cancer Research), Olivier Mir(Institut Gustave Roussy), Bernd Kasper(Heidelberg University), I. Boukovinas, Andreas Leithner(Medical University of Graz), Judith V.M.G. Bovée(Leiden University Medical Center), Antonio López–Pousa(Hospital de Sant Pau), F. Gouin(Centre Léon Bérard), Christiane Jungels(Université Libre de Bruxelles), Franel Le Grange(University College London Hospitals NHS Foundation Trust), Axel Le Cesne(Institut Gustave Roussy), Heikki Joensuu(Orion Corporation (Finland)), Jyoti Bajpai(Homi Bhabha National Institute), Andrea Ferrari(University of Milan), A.B. Hassan(University of Oxford), Paul C. Jutte(University Medical Center Groningen), Silvia Gasperoni(Azienda Ospedaliero-Universitaria Careggi), N. Abecassis, Nadia Hindi(Hospital Universitario Fundación Jiménez Díaz)
Cited by 558
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k